Compare ADMA Biologics Inc (ADMA) vs ASML Holding NV (ASML) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs ASML Holding NV — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while ASML Holding NV trades at $1,770 (market cap $662.67B). The key difference: ASML Holding NV is far larger — about 311.1× ADMA Biologics Inc's market cap, and ASML Holding NV pays a 0.5% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ASML | |
|---|---|---|
Market Cap | $2.13B | $662.67B |
Sector | Health | Technology |
52-Week High | $20.38 | $1.99K |
52-Week Low | $7.60 | $689.63 |
Enterprise Value | $2.20B | $656.21B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ASML trades at $1,747.28, down 1.25% amid semiconductor sector volatility. The stock shows strong fundamentals with 2025 revenue of $32.67B and net income of $9.61B, supported by robust profitability margins. Technical indicators are neutral, with support near $1,748. Recent news highlights AI-driven demand and geopolitical risks in chip supply chains.
Outlook remains positive given ASML's monopoly in EUV lithography and analyst consensus price target of $2,210. Risks include cyclical semiconductor demand and geopolitical tensions. Earnings beat in Q1 2026 reinforces growth trajectory, but high valuations require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →
